CHINA REGENERATIVE MEDICINE INTERNATIONAL LIMITED Financials China Regenerative Medicine International Limited
Equities
8158
KYG2129W1380
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.185 HKD | +1.65% |
|
-35.09% | -66.36% |
Valuation
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 2,902 | 1,319 | 182.9 | 1,627 | 799.2 | 316.8 |
| Enterprise Value (EV) 1 | 3,754 | 1,626 | 172.2 | 1,653 | 825.1 | 387 |
| P/E ratio | -12.2 x | -1.11 x | -0.46 x | -2.27 x | 59.9 x | 69.6 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 3.84 x | 18.1 x | 3.81 x | 8.78 x | 2.83 x | 1.37 x |
| EV / Revenue | 4.97 x | 22.3 x | 3.59 x | 8.92 x | 2.92 x | 1.67 x |
| EV / EBITDA | -17.6 x | -3.22 x | -0.86 x | -11.9 x | 13.4 x | 32.3 x |
| EV / FCF | 69.9 x | -6.6 x | 0.4 x | -6.63 x | -6.74 x | -518 x |
| FCF Yield | 1.43% | -15.2% | 251% | -15.1% | -14.8% | -0.19% |
| Price to Book | 1.65 x | 2.18 x | 1.97 x | 28 x | 7.15 x | 3.05 x |
| Nbr of stocks (in thousands) | 87,929 | 87,929 | 87,929 | 285,429 | 285,429 | 285,429 |
| Reference price 2 | 33.00 | 15.00 | 2.080 | 5.700 | 2.800 | 1.110 |
| Announcement Date | 3/27/18 | 4/11/19 | 7/1/20 | 4/1/21 | 4/27/22 | 4/10/23 |
1HKD in Million2HKD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales 1 | 755.5 | 72.95 | 47.97 | 185.3 | 282.9 | 231.6 |
| EBITDA 1 | -213.6 | -505.3 | -199.6 | -139.3 | 61.71 | 11.98 |
| EBIT 1 | -271.4 | -570.7 | -229.5 | -141 | 61.63 | 11.81 |
| Operating Margin | -35.93% | -782.31% | -478.52% | -76.09% | 21.79% | 5.1% |
| Earnings before Tax (EBT) 1 | -257.7 | -1,353 | -456.6 | -277.3 | 64.29 | 8.267 |
| Net income 1 | -237.7 | -1,194 | -395 | -404.2 | 13.35 | 4.555 |
| Net margin | -31.47% | -1,636.01% | -823.43% | -218.1% | 4.72% | 1.97% |
| EPS 2 | -2.704 | -13.57 | -4.492 | -2.516 | 0.0468 | 0.0160 |
| Free Cash Flow 1 | 53.67 | -246.4 | 432.4 | -249.3 | -122.4 | -0.7474 |
| FCF margin | 7.1% | -337.75% | 901.39% | -134.49% | -43.27% | -0.32% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/27/18 | 4/11/19 | 7/1/20 | 4/1/21 | 4/27/22 | 4/10/23 |
1HKD in Million2HKD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 852 | 307 | - | 26.5 | 25.9 | 70.2 |
| Net Cash position 1 | - | - | 10.7 | - | - | - |
| Leverage (Debt/EBITDA) | -3.991 x | -0.6068 x | - | -0.1904 x | 0.4196 x | 5.858 x |
| Free Cash Flow 1 | 53.7 | -246 | 432 | -249 | -122 | -0.75 |
| ROE (net income / shareholders' equity) | -9.9% | -108% | -153% | 1,544% | 183% | 4.22% |
| ROA (Net income/ Total Assets) | -5.44% | -14.4% | -14.5% | -25% | 18.7% | 2.76% |
| Assets 1 | 4,374 | 8,283 | 2,721 | 1,620 | 71.32 | 165.1 |
| Book Value Per Share 2 | 20.00 | 6.890 | 1.060 | 0.2000 | 0.3900 | 0.3600 |
| Cash Flow per Share 2 | 2.780 | 0.2300 | 0.2200 | 0.0200 | 0.0300 | 0.0100 |
| Capex 1 | 9.1 | 13.2 | 2.19 | - | 0.81 | 2.59 |
| Capex / Sales | 1.2% | 18.12% | 4.57% | - | 0.29% | 1.12% |
| Announcement Date | 3/27/18 | 4/11/19 | 7/1/20 | 4/1/21 | 4/27/22 | 4/10/23 |
1HKD in Million2HKD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -66.36% | 7.09M | |
| -4.02% | 184B | |
| -0.75% | 108B | |
| -2.97% | 67.82B | |
| +4.48% | 51.05B | |
| +9.09% | 44.67B | |
| +3.40% | 41.78B | |
| +3.12% | 26.78B | |
| +4.10% | 26.59B | |
| +15.23% | 25.86B |
- Stock Market
- Equities
- 8158 Stock
- Financials China Regenerative Medicine International Limited